PD-1 VEGF CTLA-4 - Business-News-Today.com

🧬 Interested in pharma, biotech and medical device news? Visit PharmaDeviceNews.com →

Business news, market intelligence, and global industry analysis.

The Latest

Editorial infographic showing the proposed combination of Panzani and Cerealis, highlighting an indicative €1.8 billion enterprise value, about €1 billion in combined annual revenue, nearly 1,800 employees, a 2025 revenue base of €620 million for Panzani and €400 million for Cerealis, and a European footprint spanning France, Portugal, Spain, the Netherlands and Central Europe.

Panzani and Cerealis plan €1.8bn European food group with €1bn in annual revenue

Mesoblast (ASX: MSB) reports US$99m cash after stronger Ryoncil sales and lower expenditure

Capital Limited (LSE: CAPD) revenue jumps 23% as Fortescue drilling deal expands

Jupiter Fund Management (LSE: JUP) assets hit £75.9bn as investor inflows return

Read More

Pharma Industry News

CStone Pharmaceuticals advances CS2009 clinical trial, targeting multi-billion-dollar immunotherapy market

CStone Pharmaceuticals has officially commenced the Phase I clinical trial for CS2009, a cutting-edge PD-1/VEGF/CTLA-4 trispecific antibody, marking…

byPallavi Madhiraju

March 4, 2025

web analytics